Poster Presentations

Poster Tour

PT 13 | Spatial dynamics between resident immune cells involve an IFNγ and IL15 axis in immune checkpoint blockade-induced muscle toxicity
Julian Dal-Cin (France)

PT 20 | Development and validation of the MDA-FI Score: a simple prognostic tool at diagnosis in anti–MDA5 dermatomyositis
Quentin Astouati (France)

PT 87 | Risk and survival of second primary cancers in patients with idiopathic inflammatory myopathies
Weng Ian Che (China)

PT 102 | An application of group-based trajectory modelling to identify distinct initial 3-month trajectories of anti-MDA5 autoantibody levels in patients with dermatomyositis: a pilot study in a myositis referral centre
Akira Yoshida (Japan)

PT 290 | The MyoScreen Study – Investigating the Utility of Blood-Based Liquid Biopsy as a Method of Cancer Screening in People with Idiopathic Inflammatory Myopathy
Chhavi Mahajan (UK)

PT 291 | Semi-quantitative measurement of myositis-specific autoantibodies in patient sera using multiplex immunoassays: within lot and lot-to-lot variability of testing
Sarah Tansley (UK)

PT 298 | Real-time MRI and quantitative muscle ultrasound for characterization of dysphagia in IBM and OPMD
Rachel Zeng (Germany)

PT 332 | Comparison of CT and MRI for detecting soft tissue calcifications in the thighs of patients with long-term juvenile dermatomyositis
Helga Sanner (Norway)

Poster Display

P 5 | Clinical characteristics and concordance of anti-MDA5 autoantibodies: A multicentre Australian study
Ali Syed (Australia)

P 6 | The histological features of anti-synthetase syndrome
Ali Syed (Australia)

P 9 | AI-enhanced nailfold capillaroscopy defines a microangiopathy signature of active idiopathic inflammatory myopathies and improves clinical stratification
Jorge Álvarez Troncoso (Spain)

P 23 | Predictors of Long-term Radiographic Changes and mortality in Patients with Idiopathic Inflammatory myopathies using Quantitative Imaging Analysis: Real World Experience from a Single-Center Longitudinal Cohort
Sangmee Bae (USA)

P 27 | Dysregulated pathways and potential biomarkers in dermatomyositis plasma-derived extracellular vesicles
Avital Baniel (Israel/USA)

P 29 | SIGLEC1 is a biomarker of disease activity in idiopathic inflammatory myopathies
Nathan Barreth (Canada)

P 30 | ICD-11: The Opportunity to Improve Disease Coding in Idiopathic Inflammatory Myopathies
Iazsmin Bauer Ventura (USA)

P 34 | A Hungarian multicentric study of anti-MDA5 positive myositis patients
Levente Bodoki (Hungary)

P 38 | Type-I Interferon-Stimulated Gene Expression is Associated with Treatment Response to Baricitinib in UK Adult Idiopathic Inflammatory Myopathy Patients
Luke Tomlinson (UK)

P 43 | antisynthetase syndrome at a tertiary centre: clinical features and agreement between class, connors and solomon criteria
Catarina Rua (Portugal)

P 64 | THE CLINICAL CONCORDANCE OF ANTI-SAE1 ANTIBODIES TESTED WITH LINE IMMUNOBLOT ASSAY TECHNIQUES
Michelle Lin (Australia)

P 68 | Epidemiology of Cancer in Idiopathic Inflammatory Myopathies: a Systematic Review and Proportional Meta-Analysis.
Joost Raaphorst (Netherlands)

P 75 | Nailfold videocapillaroscopy findings in patients with anti-aminoacyl-tRNA synthetase antibodies
Yasuhito Hamaguchi (Japan)

P 86 | Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc (Canada)

P 90 | Potential role of an increased Interferon gene signature score at baseline for the prediction of a positive response to Anifrolumab in refractory juvenile dermatomyositis
Peter Korsten (Germany)

P 98 | Revisiting “Triple M”: evidence against neuromuscular junction involvement in immune checkpoint inhibitor toxicity
Elke Schipani (USA)

P 108 | Cluster analysis identifies anti-synthetase syndrome as a distinct and heterogeneous clinical entity: Analysis from the Classification Criteria for Anti-Synthetase Syndrome project database
Akira Yoshida (Japan)

P 110 | Newly developed ELISA for detection of circulating calprotectin in serum and plasma
Tanja Seifert (Germany)

P 111 | Serum miRNA expression profiling reveals distinct regulatory networks and potential biomarkers in dermatomyositis.
Daniel Andersson (Sweden)

P 120 | Variable ANA associations among patients with Myositis Specific and Associated antibodies: real world experience from an Australian testing centre
Nicholas Villaluz (Australia)

P 123 | Immune Checkpoint Inhibitor–Related Myotoxicity: Clinical spectrum, predictors of severity, and development of a pragmatic prognostic score
Sami Tayb-Boulahfa (France)

P 131 | microvascular involvement in the idiopathic inflammatory myopathies
Tabitha John (UK)

P 133 | Real-world application of the International Myositis Assessment and Clinical Studies Group guidelines on cancer risk stratification
Silvia Cavalli (Italy)

P 138 | Optoacoustic imaging as a potential non-invasive biomarker in inclusion body myositis
Stefanie Meyer (Germany)

P 140 | reclaim-pm: a retrospective reclassification of patients diagnosed as polymyositis using contemporary clinico-sero-pathological criteria
Julian Sehne (Germany)

P 145 | Distribution patterns and predictive value of IgG, IgA and IgM autoantibody isotypes in anti-synthetase syndrome and interstitial lung disease
Antonella Notarnicola (Sweden)

P 147 | Distinct thigh muscle MRI patterns across idiopathic inflammatory myopathy subtypes: A single-center cohort analysis
Heejae Jung (Republic of Korea)

P 148 | Cardiac MRI T1 and T2 Mapping Changes in Myositis Following Im-munosuppressive Therapy: A Prospective Observational Study
Soeren Jaeger Rahbek (Denmark)

P 151 | Assessing the diagnostic utility of baseline creatine kinase levels in patients with suspected idiopathic inflammatory myopathies and neuromuscular disorders.
Nikola Wilk (Canada)

P 152 | Spectrum and Prognosis of Anti-SMN Antibody–Positive Patients: A Retrospective Cohort Study and Systematic Review of the Literature
Yves Allenbach (France)

P 155 | AI analysed FDG PET/CT as a marker of temporal changes in muscle inflammation in newly diagnosed idiopathic inflammatory myopathies: A prospective cohort study
Niclas Hansen (Denmark)

P 169 | A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies
Tanya Chandra (USA)

P 173 | Cell-free DNA Plasma Levels in Idiopathic Inflammatory Myopathies as a Potential Biomarker of Muscle Involvement
Hana Wünsch (Czech Republic)

P 188 | Multi-ancestry Genome-wide Association Study of Creatine Kinase Highlights the Genetic Basis of Muscle Damage
Gang Chen (UK)

P 190 | Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: a systematic review and meta-analysis
Takahisa Gono (Japan)

P 203 | Clinical Characteristics and Cancer Risk of Anti-OJ Antisynthetase Syndrome : A Cohort Comparative Study and a Systematic Literature Review
Yves Allenbach (France)

P 218 | T1/T2 Mapping as Potential Imaging Biomarkers for Early Idiopathic Inflammatory Myopathies; An exploratory cross-sectional study
Shereen Paramalingam (Australia)

P 219 | Whole-body magnetic resonance imaging characterization and clinical features of anti-HMGCR immune-mediated necrotizing myopathy
Belen Miguel-Ibañez (Spain)

P 221 | Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Rachel Sauls (USA)

P 223 | malignancy screening of dermatomyositis patients in the penn state registry of inflammatory myopathies (primo)
Jacob Colello (USA)

P 232 | Does The 2023 Idiopathic Inflammatory Myopathy Cancer Screening Guideline Enable Accurate Risk Stratification? Results from 18 International Cohorts
Alexander Oldroyd (UK)

P 234 | Azathioprine-induced lymphomatoid granulomatosis in a patient with dermatomyositis: a case report
Maria Diana Pascoal (Portugal)

P 240 | Newly developed ChLIA for detection of fluid calprotectin in serum
Tanja Seifert (Germany)

P 247 | Comparison of rule-based algorithms to the 2017 EULAR/ACR Classification Criteria to identify patients with idiopathic inflammatory myopathies in electronic health records
Ana Valle (USA)

P 258 | Immune-mediated necrotizing myopathy in the Portuguese population – a multicentric nationwide study
Anita Cunha (Portugal)

P 270 | Plasma Expression of Selected miR-133a-3p and miR-1-3p in Patients with Idiopathic Inflammatory Myopathies Compared Associates with Disease-related Features and Predicts Treatment Response
Martin Klein (Czech Republic)

P 271 | Cancer Risk and Survival in Idiopathic Inflammatory Myopathy: Subtype Impact in a Large, Diverse Cohort
Amir Sabouri (USA)

P 300 | Real-time MRI with deep-learning based lung segmentation for assessing respiratory involvement in inclusion body myositis
Rachel Zeng (Germany)

P 309 | Incidence and Characteristics of Antisynthetase Syndrome: A Quadruple-Source Capture-Recapture Survey Using the American College of Rheumatology/European League Against Rheumatism Classification Criteria
Margherita Giannini (France)

P 311 | The spectrum of non-specific and overlap myositis: clinico-sero-pathological characteristics.
Lung Jeung (Netherlands)

P 313 | Interlaboratory agreement in the identification of myositis-specific and myositis-associated autoantibodies by immunoprecipitation-based techniques
Sarah Tansley (UK)

P 315 | Anti-TRIM72 Antibodies in Idiopathic Inflammatory Myopathies
Eugene Krustev (USA/Canada)

P 319 | Myasthenia Gravis-Myositis Overlap: A Comparative Study of Idiopathic and Immune Checkpoint Inhibitor-Related Forms
Antonio Lauletta (Italy)

P 322 | Performance of Particle-based Multi-analyte Technology for the Detection of Myositis Specific Antibodies in Both Selected and Unselected Cohorts
Lisa Peterson (USA)

P 329 | Clinical significance of anti-synthetase antibodies in patients with Rheumatoid Arthritis or undifferentiated arthritis: preliminary data from a monocentric cohort
Alberto Paladini (Italy)

P 330 | Prevalence of sarcopenia in a cohort of Danish patients with myositis: a cross-sectional study
Kasper Yde Jensen (Denmark)

P 337 | Data-Driven Subgrouping of Inflammatory Myopathy Related Clinical and Serological Profiles in a Greek cohort: Multiple Correspondence Analysis and Hierarchical Clustering
Nikolaos Marketos (Greece)

P 338 | Is the presence of concomitant myositis-related autoantibodies associated with disease severity?
Maria João Cadório (Portugal)

P 346 | Cancer and Antisynthetase syndrome : data from the CLASS project database
Thomas Moulinet (France)

P 349 | Prevalence of anti-CCP antibody in anti-synthetase syndrome, Association with certain clinical manifestations. Preliminary análisis.
Maria, M Croce (Argentina)

P 371 | Following Ferritin to Follow the Lungs: Monitoring ILD in Anti-MDA5 Dermatomyositis
Silvia Grazzini (Italy)

P 376 | Correlation of autoantibody profile and software analysis of well- aerated lung in myositis patients affected by interstitial-lung disease.
Angela Ceribelli (Italy)

Poster Tour

PT 53 | Efficacy of a Novel Multitargeted Regimen Combining Baricitinib, Rituximab, and Tacrolimus (BRT-Tx) for Anti-MDA5 Antibody–Positive Dermatomyositis: A Comparative Transcriptomic Study
Yoshinobu Koyama (Japan)

PT 132 | Defining CDASI Thresholds of Disease Severity: Integrating Physician Assessments of Disease Activity with Patient Perspectives on Quality of Life
Sarah Jun (USA)

PT 134 | Family History of Autoimmunity and Herbal Supplement Use in Dermatomyositis: Associations with Disease Activity
Sarah Jun (USA)

PT 141 | Predictors of fatigue in a Swedish cohort of patients with idiopathic inflammatory myopathies
Karin Lodin (Sweden)

PT 164 | Outcomes of Immunosuppression in Myositis-associated Interstitial Lung Disease based on Radiological Phenotypes among a Large Indian Cohort
Akshay Raju (India)

PT 170 | Statin Exposure and Clinical Outcomes in Anti-HMGCR Immune-Mediated Necrotizing Myopathy
Marwin Groener (USA)

PT 200 | In vitro screening of nucleic acid therapies targeting IFN beta as a novel therapeutic approach for adult and juvenile dermatomyositis
Joanna E Parkes (UK)

PT 277 | AN INITIAL GENOME-WIDE ASSOCIATION ANALYSIS OF DERMATOMYOSITIS IN ~2.1 MILLION INDIVIDUALS FROM THE DERMATOMYOSITIS GENETICS CONSORTIUM (DMGC)
Galen Foulke (USA)

Poster Display

P 10 | KL-6 predicts interstitial lung disease and progression in idiopathic inflammatory myopathies: a one-year cohort with serial HRCT and pulmonary function testing
Jorge Álvarez Troncoso (Spain)

P 12 | The MIGHT TRIAL – An Exploratory Clinical Trial of IVIG in anti-HMGCR Immune-Mediated Necrotizing Myopathy
James Andrews (USA)

P 18 | Respiratory Muscle Strength Training in the Myositis Population
Meaghan Arnold (USA)

P 22 Anti-synthetase syndrome (ASyS) related interstitial lung disease (ILD) is associated with distinct phenotype and poor prognosis as compared to other ILDs: Classification Criteria for Anti-Synthetase Syndrome (CLASS) project analysis.
Sangmee Bae (USA)

P 39 | Low-Dose IL-2 Add-on Therapy Reduces Infection Incidence in Idiopathic Inflammatory Myopathy: A Prospective Cohort Study
Yuhui Li (China)

P 40 | Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Analysis
Kun Huang (Canada)

P 41 | Clinical characteristics and evolution of interstitial lung disease in subtypes of idiopathic inflammatory myositis patients with prevalent lung manifestation: a retrospective analysis
Kun Huang (Canada)

P 51 | Electrocardiogram abnormalities in patients with new-onset myositis.
Fabricio Espinosa Ortega (Sweden)

P 55 | Interstitial lung disease in systemic autoimmune rheumatic diseases: radiologic and histologic correlations
Océane Landon-Cardinal (Canada)

P 58 | Clinical Trials in Idiopathic Inflammatory Myopathies – A longitudinal analysis of patterns in study design, therapeutic targets and outcome measures
Jisna Paul (USA)

P 60 | Treatment patterns and drug use in idiopathic inflammatory myopathies. Description of the first year after diagnosis in a Swedish myositis cohort.
Irene Peralta Garcia (Sweden)

P 63 | The interplay between infections and immunogenetics in the pathogenesis of idiopathic inflammatory myopathies.
Dorota Lebiedz-Odrobina (USA)

P 67 | Sustained disease control with rituximab maintenance in anti-synthetase syndrome: insights from a real-life cohort
Silvia Grazzini (Italy)

P 71 | Systematic Literature Review of the Properties of Outcome Measurement Instruments in Idiopathic Inflammatory Myopathies
Latika Gupta (UK)

P 83 | Efficacy of Rituximab in Patients with Idiopathic Inflammatory Myopathies Refractory to csDMARDs – Preliminary Results of a Prospective Observational Monocentric Study over 24 Months
Daniel Zavada (Czech Republic)

P 101 | Teclistamab-induced Rapid Remission in Refractory Anti-Jo-1 Antisynthetase Syndrome
Elpida Phithak (Germany)

P 112 | Objective evaluation of gastrointestinal involvement in anti-synthetase syndrome
Clara Edo-Fernández (Spain)

P 113 | Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Shiri Keret‬ (Israel)

P 116 | Pulmonary findings in high resolution computed tomography according to the diagnosis and myositis autoantibodies. Results from the MYOTReCSZ cohort.
Samuel Govea-Peláez (Mexico)

P 119 | Disseminated enterovirus infection associated with severe immune mediated myositis in a patient presenting with anasarca and proximal myopathy
Anna Brusch (Australia)

P 125 | Hand exercise in people with inclusion body myositis-A Single Subject Design
Malin Regardt (Sweden)

P 129 | Case series: Successful rescue treatment of 3 cases of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab
Choon Guan Chua (Singapore)

P 130 | Cutaneous Clues: Distinguishing Anti-Synthetase Syndrome from Dermatomyositis
Edoardo Conticini (Italy)

P 153 | Beyond Statins: Alternative Triggers in Anti-HMGCR IMNM Case Series and review of the literature
Mariana Emília Santos (Portugal)

P 156 | acute kidney injury in hospitalized patients with idiopathic inflammatory myopathies
Dante Dahabreh (USA)

P 159 | use of anifrolumab in a patient with refractory dermatomyositis: a case report
Alsayed Osman (USA)

P 162 | Feasibility of a 16-week exercise intervention for patients with inclusion body myositis: adherence, safety and experiences from patients and physiotherapists
Kristine Risum (Norway)

P 178 | Prioritizing Drug Targets for Idiopathic Inflammatory Myopathies via QTL-Based Mendelian Randomization and Colocalization
Gang Chen (UK)

P 179 | Chin Tuck Against Resistance (CTAR) Training for Swallowing Function in Patients with Myositis: Experience from a standardized clinical intervention
Dilara Erer (Sweden)

P 184 | Interstitial Lung Disease in Mixed Connective Tissue Disease: A Distinct Clinical Pattern Compared to Systemic Sclerosis and Myositis?
Filipa Costa (Portugal)

P 185 | Reconstitution of the B-cell compartment following anti-CD19 CAR T-cell therapy in refractory patients with juvenile dermatomyositis (JDM)
Rebecca Nicolai (Italy)

P 189 | Characteristics and Outcomes in Patients with Anti-synthetase syndrome (ASyS) related interstitial lung disease (ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” project database.
Francisca Bozan (Chile)

P 191 | Comparison between the Camry and Jamar Dynamometers for Measurement of Hand Grip Strength in Inclusion Body Myositis
Kelly Beer (Australia)

P 193 | Assessment of cardiac health in stable patients with myositis following 16 weeks of high-intensity resistance training
Kasper Yde Jensen (Denmark)

P 194 | Gastrointestinal involvement in idiopathic inflammatory myopathies: a common clinical observation
Albert Gil-Vila (Spain)

P 224 | Predictors for Interstitial Lung Disease in Anti-MDA5/Anti-synthetase antibody Negative IIM Patients: Insights from the Hong Kong myositis registry
Iris Yan Ki Tang (China)

P 225 | Global patterns and challenges in patient enrolment for idiopathic inflammatory myopathy clinical trials: results from the MCTC Investigators’ Survey
Iris Yan Ki Tang (China)

P 226 | Smoking habits in UK patients with idiopathic inflammatory myopathy – insights from the UK MYOPROSP cohort
Aleksandra Opinc-Rosiak (Poland)

P 227 | Environmental and lifestyle exposures associated with interstitial lung disease and cardiac involvement in idiopathic inflammatory myopathy: analysis from the UK MYONET cohort
Aleksandra Opinc-Rosiak (Poland)

P 228 | does covid-19 infection impact cardiovascular risk in idiopathic inflammatory myopathy? findings from whole-population data in england
Eva Henning (UK)

P 233 | Effect of exercise on functional decline in Inclusion Body Myositis
Bhaskar Roy (USA)

P 249 | risk factors for progressive pulmonary fibrosis and mortality in the antisynthetase syndrome–associated ild: a cohort study
Daphne Rivero Gallegos (Mexico)

P 250 | the severity of interstitial lung disease in antisynthetase syndrome during its acute phase: incidence of acute respiratory distress syndrome
Montserrat Ixchel González Pérez (Mexico)

P 254 | Prognostic factors and treatments for immune mediated necrotizing myositis
Charlotte Sierra (France)

P 265 | Longitudinal Trajectories of Antisynthetase Syndrome-Associated Interstitial Lung Disease
Paul Decker (France)

P 273 | Evaluating ChatGPT’s advice and recommendations regarding exercise for people with Inclusion Body Myositis
Ian Cooper (Australia)

P 276 | A pilot study to evaluate the efficacy of an at-home TheraPutty® hand exercise intervention on strength and function in adults with Inclusion Body Myositis (IBM)
Ian Cooper (Australia)

P 283 | association of anti–aminoacyl-trna synthetase antibody subtypes with severity and evolution of interstitial lung disease: an analysis of the class project database
Daphne Rivero Gallegos (Mexico)

P 292 | Comprehensive myositis antibody panels improve recognition of idiopathic inflammatory myopathy related interstitial lung disease
Erica Ludtke (USA)

P 297 | Integrating Digital Technology in Exercise in Myositis and Introduction of a New Mobile-Exercise App, MyoRxercise
Suur Biliciler (USA)

P 303 | Lung-Dominant Anti-SRP Autoimmunity: A Distinct Clinical Subset Characterized by Isolated Interstitial Lung Disease Without Myopathy
Illiasul Ibad (India)

P 310 | Personalized rehabilitation in severely fatigued myositis patients (PRO-FIT): study protocol of a pilot randomized controlled trial
Nienke Heida (Netherlands)

P 316 | A multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in idiopathic inflammatory myopathies: first results of the DRIMID study
Merve Kocyigit (Netherlands)

P 324 | joint involvement in anti-synthetase syndrome: preliminary analysis from the class project database
Carolina Vilafanha (Portugal)

P 328 | A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index
Xinxin Zhang (China)

P 335 | Drug-induced myositis in Oncology: Immune checkpoint inhibitors myotoxities and beyond
Yves Allenbach (France)

P 339 | Do anti-MDA5 autoantibody titers correlate with disease severity and poor outcomes in idiopathic inflammatory myopathies?
Filipa Canhão André (Portugal)

P 352 | Fatty acid binding protein 3 (FABP-3) is a potential mediator of muscle damage in inflammatory myopathies and its serum level decrease in response to a high intensity exercise program
Margherita Giannini (France)

P 353 | Predictors of interstitial lung disease progression in Antisynthetase Syndrome
Marthe Mæhlen (Norway)

P 358 | Decentralized Recruitment Efficiency in a Rare Disease Trial: Insights from the Myositis Interstitial Lung Disease Nintedanib Trial (MINT)
Rohit Aggarwal (USA)

P 372 | when coffee turns toxic: hmgcr immune-mediated necrotizing myopathy linked to mushroom supplements
Lakshmi Jayaram (USA)

P 375 | Physical function and patient-reported outcomes following a 16-week exercise intervention in patients with inclusion body myositis: results from a feasibility study
Kristine Risum (Norway)

P 385 | Corticosteroid Dependency Among Adult Patients with Dermatomyositis in the United States
Katharina Shaw (USA)

Poster Tour

PT 32 | Leading through lived experience: International learnings in patient-led research and partnership in myositis
Kelly Beer (Australia)

PT 84 | Early interferon priming and late metabolic reprogramming define longitudinal trajectories in inclusion body myositis
Felix Kleefeld (Germany)

PT 209 | Application of a Semi-Quantitative Ultrasound Grading Scale for Assessing the Severity of Muscle Involvement in Inclusion Body Myositis
Myma Albayda (USA)

PT 268 |  Single Nuclei Multiome of Juvenile Dermatomyositis Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
Shannon O’Connor (USA)

PT 299 | Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): a double-blind placebo-controlled randomized trial
Pinar Özkaynar (Netherlands)

PT 363 | single-cell profiling reveals interferon-high proliferation in jdm versus nfkb-driven inflammation in csle across naive b and cd56dim cd16+ nk Cells
Li Chen (USA)

PT 366 | Comparative evaluation of clinical outcome measures in inclusion body myositis based on NT5c1A antibody serology status
Marie Wencel (USA)

Poster Display

P 7 | Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Maha Almackenzie (Saudia Arabia)

P 15 | Identifying Targets for Interventions to Reduce Emotional Distress and Improve Physical Activity in Juvenile Dermatomyositis and Lupus Patients:
Kaveh Ardalan (USA)

P 16 | Positive Affect and Emotion Regulation Protect Juvenile-Onset Dermatomyositis and Lupus Patients from Emotional Distress:
Kaveh Ardalan (USA)

P 24 | Interstitial Lung Disease In Juvenile Dermatomyositis: Clinical Correlates Of Radiological Patterns
Narendra Bagri (India)

P 48 | THE IMPACT OF FATIGUE IN JUVENILE DERMATOMYOSITIS
Silvia Rosina (Italy)

P 54 | Cognitive Dysfunction in Myositis: An Under-recognized Clinical Phenotype and Associated Factors.
Mustafa Ekici (Türkiye)

P 72 | ‘Your body is doing something you don’t want it to’: Understanding the health journeys of Aboriginal people with muscle diseases
Thomas Khoo (Australia)

P 76 | Tertiary Pediatric Rheumatology Centre experience with Fitness testing in Idiopathic Inflammatory Myopathies of childhood.
Verna Cuthbert (UK)

P 78 | Beyond the diagnosis: A qualitative study exploring patient and parent experiences of living with juvenile dermatomyositis
Lisa McCann (UK)

P 79 | First study of bioengineered muscle from a JDM patient reveals distinct response to type I interferon
Lauren Covert (UK)

P 80 | Sensitivity and positive likelihood ratios of myositis-specific autoantibodies with specific clinical features in juvenile dermatomyositis in a large real-world multi-site registry
Belina Yi (USA)

P 94 | Myofiber Necrosis and Complement (C5b-9) Deposition in Inclusion Body Myositis: Frequency and Pathologic Associations
Mustafa Ekici (Türkiye)

P 95 | When good B cells go bad: cN1A-reactivity in inclusion body myositis.
Nataliya Slater (Australia)

P 96 | GBP6: a highly specific Interferon gamma-dependent serum and tissue biomarker for Inclusion Body Myositis
Corinna Preusse (Germany)

P 97 | Single-Center Experience in Juvenile Dermatomyositis: Diagnostic Delays, Myositis-Specific Antibody Profiles, and Calcinosis
Mehmet Erkan (Türkiye)

P 106 | Dysphagia Has a Major Impact on Quality of Life in Idiopathic Inflammatory Myopathies – A Patient-Reported Cross-sectional Study
Fulden Sari (Sweden)

P 109 | Detection of autoantibodies against cN-1A using a multiparameter lineblot for autoimmune inflammatory myopathies
Tanja Seifart (Germany)

P 115 | Fatigue impacts the quality of life of patients with myositis, regardless of age, sex, and muscle strength
Maria Diana Pascoal (Portugal)

P 128 | Exploring relationships between the IBMFRS and transitional ambulatory phases and the impact on fall risk in patients with Inclusion Body Myositis (IBM): INSPIRE-IBM
Stephanie Hunn (USA)

P 149 | Engineered human muscle models the interferon-driven transcriptome of juvenile dermatomyositis muscle
Lauren Covert (USA)

P 157 | From operating room to outpatient clinic: needle biopsy for neuromuscular diagnostics
Karsten Krause (Germany)

P 165 | Contextualizing Sexual Well-being in Idiopathic Inflammatory Myopathies
Lakshmi Minikumari Rahulan (India)

P 171 | Methodology report: International recommendations for the management of juvenile idiopathic inflammatory myopathies (JIIM) – an IMACS-CARRA-PReS cross-party initiative, supported by Cure JM.
Belina Yi (USA)

P 174 | Persistent pulmonary impairment and elevated IL-18 define the interstitial lung disease phenotype in juvenile dermatomyositis
Charalampia Papadopoulou (UK)

P 182 | EOS® imaging system is a novel, rapid, safe, and effective technique to detect and assess calcinosis in JDM
Jessica Perfetto (USA)

P 183 | African children with JDM present with severe disease and have worse outcomes over time compared to North American children
Jessica Perfetto (USA)

P 195 | Estimating Meaningful Score Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Self-Report and Parent-Proxy Measure Scores in Juvenile Myositis
Madison Wolfe (UK)

P 199 | Recovery of Th1 cell frequency is associated with clinical remission of Juvenile Dermatomyositis
Nia M L Evans (UK)

P 207 | Patient journey, healthcare resource utilization, and mortality in IBM: a US-based claims analysis
Elie Naddaf (USA)

P 212 | Utility of the Mawdsley Calcinosis Questionnaire in Patients with Juvenile Dermatomyositis Associated Calcinosis
Adam Schiffenbauer (USA)

P 215 | Comparative evaluation of respiratory assessments in inclusion body myositis from INSPIRE-IBM study.
Isela Hernandez (USA)

P 230 | Type I interferon signature is associated with disease activity and muscle outcomes in juvenile dermatomyositis
Silvia Rosini (Italy)

P 231 | Nutritional status and body composition in patients with idiopathic inflammatory myopathies
Stefanie Glaubitz (Germany)

P 244 | Anabolic Resistance in Inclusion Body Myositis versus Healthy Ageing: Insights from an Ex Vivo-In Vitro Model
Charlotte Linscott (UK)

P 245 | Application of Ultrasound-Guided Cryo-Fracture Biopsy for Muscle in Pediatric Idiopathic Myositis
Xinning Wang (China)

P 259 | Single-cell spatial transcriptomic profiling reveals abnormal interferon and metabolic signatures in juvenile dermatomyositis muscle tissue
Aris E Syntakas (UK)

P 261 | Comparison of Disease Severity and Activity Between Juvenile- and Adult-Onset Dermatomyositis: A Multicenter Cohort Study
Paul Decker (France)

P 262 | Assessing in vivo brain amyloid deposition in inclusion body myositis using positron-emission tomography
Sharfaraz Salam (UK)

P 263 | Quantitative MRI of Forearm Muscles as a Biomarker in Inclusion Body Myositis
Sharfaraz Salam (UK)

P 264 | Wearable-Based Monitoring of Physical Activity and Upper Limb Function in Inclusion Body Myositis
Mazen Dimachkie (USA)

P 272 | Prevalence of Inclusion Body Myositis in Western Australia: Mapping changes over 25 years
Genevieve Simkovics (Australia)

P 285 | Through Their Eyes: Acceptability of Nailfold Capillaroscopy in Children with Juvenile Dermatomyositis. A mixed-methods study
Liza McCann (UK)

P 305 | Algorithm for Identifying US Veterans with Inclusion Body Myositis from the Corporate Data Warehouse
Vladimir Liarski (USA)

P 306 | Inducible nitric oxide synthase deficiency reduces β-amyloid burden in skeletal muscle and improves running performance in a mouse model of inclusion body myositis
Jens Schmidt (Germany)

P 312 | Proteomic composition of COX-SDH abnormal fibres in Polymyositis with mitochondrial pathology
Karsten Krause (Germany)

P 320 | Cardiac dysfunction is associated with reduced cardiorespiratory fitness in long-term juvenile dermatomyositis
Helga Sanner (Norway)

P 334 | Myositis Patient Journey Qualitative Research and Co-Creation
Edward Banfe (USA)

P 336 | COMPARISONS BETWEEN ADULT AND JUVENILE DM PERIPHERAL BLOOD MONONUCLEAR CELL GENE EXPRESSION MAY IDENTIFY CANCER-ASSOCIATED GENE SIGNATURES
Galen Foulke (USA)

P 340 | A case of chronic inflammatory anti-HMGCR myopathy with features of inclusion body myositis
Julia Wanschitz (Austria)

P 342 | Mental Health Burden in Idiopathic Inflammatory Myopathies: A Comparative Population-Based Study
Bianca Paulo Correia (Portugal)

P 343 | Novel mouse model for inclusion body myositis: transgenic upregulation of lymphotoxin together with impaired autophagy induces inflammation and protein accumulation in skeletal muscle
Jens Schmidt (Germany)

P 347 | establishment of a global patient-centered registry for idiopathic inflammatory myopathies – the my pacer study
Akira Yoshida (USA)

P 350 | Patient-based myositis registry in Germany
Karsten Kummer (Germany)

P 351 | Comparison between idiopathic inflammatory myopathies and rheumatoid arthritis: from a shared physical impairment to different quality of life outcomes.
Linda Carli (Italy)

P 356 | Combined Resistance and Endurance Exercise Decreases Disability and Improves Physical Capacity in Established Inflammatory Myopathies: A Hospital- vs Community-Based Prospective Study
Margherita Giannini (France)

P 357 | Pulmonary Involvement Across Juvenile-Onset Connective Tissue Diseases: Results from a National Multicentre Cohort
Carolina Zinterl (Portugal)

P 360 | Mental Health Coping Strategies Practiced by People Living with Myositis: Results of a Qualitative Survey
Paula Eichenbrenner (USA)

P 361 | Statin Exposure May Affect the Trajectory of Disease Over Time in Inclusion Body Myositis
Mayank Kalra (USA)

P 362 | nailfold capillaroscopy changes across a dual center cohort of juvenile dermatomyositis patients
Aurora Rynda (USA)

P 364 | endothelial cell mediators reflecting angiopoietin and interferon pathway activation characterize juvenile dermatomyositis disease activity and autoantibody subgroups
Kirsten Grant (USA)

P 369 | Imaging mass cytometry identifies a population of granzyme K+ CD8+ T cells in inclusion body myositis
Philip Farahat (USA)

P 373 | Patient perspectives on nutrition in Idiopathic Inflammatory Myopathies: An analysis of online discussions
Peter Kerkhof (Netherlands)

P 377 | Caregiver Burden in Inclusion Body Myositis: A cross-sectional study of 124 IBM caregivers
Dhruv Nandakumar (USA)

P 383 | BIOENGINEERED MUSCLE-ON-A-CHIP AS A MODEL OF INCLUSION BODY MYOSITIS
Félix Andújar-Sánchez (Spain)

P 387 | Observational Study of Inclusion Body Myositis: Functional Trajectories and Treatment Exposure in Brazilian and French Cohorts
Bruna Moreira de Souza Proença (Brazil)

P 390 | Early Functional Decline in Inclusion Body Myositis Detected by the Motor Function Measure: A Longitudinal Observational Study
Bruna Moreira de Souza Proença (Brazil)

Poster Tour

PT 85 | Spatial transcriptomics in immune-mediated necrotizing myopathy reveals a specific necrotic signature related to immune-driven fibrosis
Julian Dal Cin (France)

PT 161 | Determinants of subjective well-being in individuals with idiopathic inflammatory myopathies
Lekshmi Minikumari Rahulan (India)

PT 255 | Prospective Muscle Biopsy Transcriptomics in Active Myositis Identifies Molecularly Distinct Subgroups
Julie Paik (USA)

PT 256 | Income-based global inequities in myositis trial readiness and engagement: findings from the MCTC investigator network
Rachid Smaili (Morocco)

PT 282 | Association of Paraoxonase 1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An Exploratory Analysis
Christina Charles-Schoeman (USA)

PT 294 | Impact of Mediterranean Diet on outcomes in patients with Idiopathic Inflammatory Myopathies
Lekshmi Minikumari Rahulan (India)

Poster Display

P 8 | Plasmacytoid Dendritic Cells and ER stress cooperate to drive fibroblast activation: implications for myositis-associated tissue fibrosis
Catarina R Almeida (Portugal)

P 14 | Seronegative dermatomyositis: do the clinical phenotype and disease course differ from seropositive dermatomyositis?
Eleonora Antonelli (Italy)

P 31 | Bringing Myositis Research to the Community: insights from a co-designed ‘Research Roadtrip’
Kelly Beer (Australia)

P 36 | CD73low B cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies
Maho Nakazawa (USA)

P 37 | Involvement of type I interferon (IFN) receptor signaling in serum-mediated muscle weakness in dermatomyositis
Cecilia Leijding (Sweden)

P 44 | Maternal-Fetal Outcomes and Risk Factors in Idiopathic Inflammatory Myopathies: a Portuguese Multicenter Study
Raquel Marques (Portugal)

P 50 | Safety and efficacy of statin therapy in patients with dyslipidemia and idiopathic inflammatory myopathies
Samuel Katsuyuki Shinjo (Brazil)

P 52 | A longitudinal cohort of patients with Idiopathic Inflammatory Myopathies with a muscle biopsy repository and a serum biobank
Andrea Kemp (Sweden)

P 56 | The role of Siglec1 in the pathogenesis of idiopathic inflammatory myopathies
Sylvia Raftopoulou (Greece)

P 61 | Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
Jiram Torres-Ruiz (Mexico)

P 62 | A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Jiram Torres-Ruiz (Mexico)

P 65 | Comparing the efficacy of conventional immunosuppression and rituximab in anti-SRP myositis: insights from a tertiary care centre experience.
Abhilasha Manwatkar (India)

P 66 | Treatment Response And Long-Term Outcomes of Idiopathic Orbital Myositis : 10 Year experience From Tertiary Care Centre
Abhilasha Manwatkar (India)

P 73 | The clinical, serological and histological features of muscle diseases in Aboriginal and Torres-Strait Islander peoples in South Australia
Thomas Khoo (Australia)

P 74 | Phenotype-based stratification of idiopathic inflammatory myopathies integrating peripheral blood single-cell transcriptomes
Shinji Izuka (Japan)

P 77 | Neutrophil extracellular traps promote interferogenic and proinflammatory responses in myeloid and muscle cells: Analysis of their potential role in the induction of perifascicular atrophy
Jiram Torres-Ruiz (Mexico)

P 82 | Heart Rate Variability Reflects Subclinical Atherosclerosis in Patients with Idiopathic Inflammatory Myopathies
Daniel Zavada (Czech Republic)

P 88 | Muscular involvement in systemic sclerosis: high mortality not associated with nature of histological lesions
Noémie Le Gouellec (France)

P 89 | Comparison of Organ Damage Development and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: A Retrospective Analysis Deciphering Different Trajectories
Ezgi Sahin (Türkiye)

P 99 | Anti-MDA5 monoclonal antibodies from patients with dermatomyositis – B cell characteristics and differential targeting of the helicase domains
Marina Galesic (Sweden)

P 103 | Idiopathic inflammatory myopathies in peru: a scoping review of published literature
Yelitza Velarde-Mejia (Peru)

P 104 | Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase
Begum Horuluoglu (Sweden)

P 105 | Study of peripheral microcirculation with laser doppler flowmetry and ice exposure in patients with Anti-synthetase Syndrome
Joana Rita Matos Caetano (Portugal)

P 114 | Gaps in training and expertise in myositis outcome measures: insights from the MCTC investigator survey
Shiri Keret‬ (Israel)

P 117 | Systemic Sclerosis–Associated Fibrosing Myopathy: A Distinct Entity with High Mortality
Julie Paik (USA)

P 126 | Long-term follow-up and risk factors for relapse in patients with anti-HMGCR necrotizing myopathy
Orane Demuynck (France)

P 127 | Impact of treatment on muscle biopsies in patients with anti-HMGCR necrotizing myopathy
Orane Demuynck (France)

P 135 | Multimodal single-cell profiling of muscle immune infiltrates and spatial transcriptomics reveal shared and disease-specific programs in idiopathic inflammatory myopathies
Tomoya Yoshida (Japan)

P 136 | Elevated ceramidase expression links sphingolipid remodeling to muscle inflammation and recovery in a murine model of myositis
Alfredo Guzman (USA)

P 142 | Sertraline-Induced MADD: Two Cases of Lipid Storage Myopathy After Prolonged SSRI Use
Swapnasha Panigrahi (UK)

P 150 | SSRI-ously Weak: A Case of Severe Myopathy Associated with Sertraline Use
Nikola Wilk (Canada)

P 160 | Myositis in anti–U1RNP–positive patients: an in-depth analysis
Marie-Therese Holzer (Germany)

P 172 | Systemic and skeletal muscle regulation of anabolic pathways in idiopathic inflammatory myopathies shows stage-dependent alterations
Lucie Lážnovská (Czech Republic)

P 175 | Enhanced Fibrogenic Pathways Define Scleromyositis Within the Spectrum of EULAR/ACR Myositis Subsets
Margherita Giannini (France)

P 176 |  Anti-Synthetase Syndrome in Argentina – A Report from the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology
Ignacio Lopez (Argentina)

P 177 | ANTIMITOCHONDRIAL ANTIBODIES IN IMMUNE-MEDIATED INFLAMMATORY MYOPATHIES: A RARE BUT CLINICALLY RELEVANT ANTIBODY
Ignacio Lopez (Argentina)

P 216 | ANTI-MDA5 DERMATOMYOSITIS IS ASSOCIATED WITH INCREASED RISK OF INFECTIONS: A REVIEW OF THE LITERATURE
Katherine Moore (Australia)

P 220 | The Australasian Myositis Registry: A National Prospective Database for Idiopathic Inflammatory Myopathies
Merrilee Needham (Australia)

P 229 | Incidence of Myositis in the UK, 2010–2024: A Retrospective Cohort Study Using Primary Care Electronic Health Records
Kimberly Loh (UK)

P 235 | A prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable Idiopathic Inflammatory Myopathy (ADAPT-study).
Sanne Evers (Netherlands)

P 236 | Interferon-β triggers Z-DNA binding protein 1-mediated PANoptosis in T cells of anti-melanoma differentiation associated protein 5 antibody-positive dermatomyositis
Xinxin Zhang (China)

P 242 | Single-cell Transcriptomic Differences in Alveolar Macrophages and Neutrophils in a Model of Melanoma-Differentiation Associated Gene 5-induced Interstitial Lung Disease
Yuki Ichimura (Japan)

P 243 | Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Outcome Measures
Lisa Rider (USA)

P 252 | Muscle Transcriptomic Profile in Patients with Dermatomyositis Without Characteristic Histopathological Findings
José Milisenda (Spain)

P 257 | Muscle inflammation drives mitochondrial impairment in a human cell stress model of autoimmune myositis (IIM)
Stefanie Meyer (Germany)

P 266 | survival and causes of death in idiopathic inflammatory myopathies: french national health data system and national database for rare diseases
Dylan Vellas (France)

P 267 | Immune Checkpoint Inhibitor-Induced Myositis: Diagnostic Features and Factors Associated with Early Unfavorable Outcomes
Lucile Duvaltier (France)

P 269 | The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023
Patrick Gordon (UK)

P 278 | A retrospective analysis of the diagnosis and treatment of sarcoid myopathy at a large academic medical center
Rachel Sauls (USA)

P 280 | Spatial transcriptomic analysis of treatment-naïve inflammatory myopathy muscle using Xenium 5K Prime panel
Jianna He (Australia)

P 286 | myositis disease and treatment landscape in the united states and germany: results from a quantitative physician survey
Shelby Wilkinson (USA)

P 293 | Steroid induced myopathy and toxicity among dermatomyositis patients using the glucocorticoid toxicity index
Joshua C. Prenner (Australia)

P 295 | Comparison of clinical characteristics between anti-MDA5 dermatomyositis and anti-synthetase syndrome patients in a southeast Asian cohort
Choon Guan Chua (Singapore)

P 301 | Chimeric NOD SCID model of myositis using peripheral blood mononuclear cells from a patient with MDA5+ dermatomyositis recapitulates disease features
Samantha Coss (USA)

P 304 |  Histidyl-tRNA synthetase-induced myositis is mediated by membranopathy and ameliorated by regulatory T cells
Samantha Coss (USA)

P 317 | Sporadic Late-Onset Nemaline Myopathy (SLONM): data from a case series and literature review of 144 patients
Antonio Lauletta (Italy)

P 318 | Mimicking conditions of Idiopathic Inflammatory Myopathies – an ADAPT sub-study
Pinar Özkaynar (Netherlands)

P 325 | Assessment of Infections and Antimicrobials as Risk Factors for IIM
Adam Schiffenbauer (USA)

P 331 | Clinical course, therapeutic management, and lipid-lowering therapy in a cohort of patients with anti-HMGCR immune-mediated necrotizing myopathy (IMNM)
Alberto Paladini (Italy)

P 341 | Evaluation of GLP-1-Receptor Agonist Use in Patients with Idiopathic Inflammatory Myopathies: A Retrospective Analysis
Joshua C. Prenner (USA)

P 344 | Notch3 suppresses regulatory T cell control of proinflammatory macrophage states
Sara Sabbagh (USA)

P 345 | Skeletal muscle expression of IL-17 family cytokines in a mouse model of myositis
Madison King (USA)

P 348 | The effects of serum, containing myositis-specific autoantibodies, on muscle fiber contractility in Immune-Mediated Necrotizing Myopathy.
Tom Kerkhoff (Netherlands)

P 355 | Unmasking the Comorbidity Landscape in Idiopathic Inflammatory Myopathies: A Population-Based Comparison
Miguel Alfonso Martins (Portugal)

P 370 | Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
José Milisenda (Spain)

P 380 | spatial transcriptomics defines focal autoantibody-driven muscle injury in anti-mi2-positive dermatomyositis
Andrew Mammen (USA)

P 382 | Induction of Experimental Autoimmune Myositis by TIF-1γ mRNA-LNP Immunization in Mice
Yuhui Li (China)

P 384 | Predictors of Mortality in Idiopathic Inflammatory Myopathy: A Nationwide Multicenter Cohort Study
Inês Sopa (Portugal)

P 386 | Spatial Characterization of the Peripheral Immune Landscape in Myositis
Celia del Carmen Crespo Oliva (Canada)

P 394 | Identifying idiopathic inflammatory myopathies from electronic health record data with natural language processing and machine learning
Ana Valle

Online Only

OP 11 | Tell Me Your Antibody and I Will Well Wou Wour Capillaroscopy Pattern
Maria João Cadório

OP 17 | Beyond the Skin and Muscle: A Case of NXP-2 Dermatomyositis with Unprecedented Gastrointestinal Catastrophe
Alexandra Arges

OP 28 | Procoagulant extracellular vesicles in patients with livedo reticularis
Avital Baniel

OP 42 | anti-synthetase syndrome: experience from a tertiary center
Catarina Rua

OP 45 | Adverse Perinatal Outcomes and Recurrent Perivillous Fibrin Deposition in Anti-Jo-1 Antisynthetase Syndrome: A Case Report
Raquel Marques

OP 46 | COULD TRIPLE THERAPY BE THE RIGHT TREATMENT FOR SEVERE IDIOPATHIC INFLAMMATORY MYOPATHIES?
Hugo Gonçalves

OP 59 | A Flare Up or an Overlap, a Case Report of Sudden Muscle Weakness in SLE Patient with Challenging Diagnosis
Gantira Danasasmita

OP 70 | A Systematic Review of Nutritional Interventions in Muscle diseases
Latika Gupta

OP 93 | Myositis and constipation: time-stratified risks of lower gastrointestinal complications in idiopathic inflammatory myopathies
Chih-Wei Tseng

OP 107 | A neurological twist in a patient with inflammatory myopathy: A rare case report.
Tomás Stein Novais

OP 122 | Cancer Incidence and Prognostic Impact of Malignancy Timing in Dermatomyositis: Data from the INMYRE Registry
Marco Fornaro

OP 137 | Clinical Profile and Outcomes of Patients with Immune -Related Adverse events to Immune Checkpoint Inhibitors
Rica Kezia King

OP 144 | Patients with Myositis; the journey from diagnosis in inpatient care to outpatient clinic care- how do we meet patient´s needs in early disease?
Ingrid Gerhardson

OP 154 | Severe Juvenile Polymyositis Triggered by Influenza A and COVID-19: A Case of Multi-Organ Involvement and Therapeutic Challenges
Joanna Lipińska

OP 158 | Psoas muscle atrophy can differentiate Spinal bulbar muscular atrophy from Amyotrophic lateral sclerosis: a retrospective study
Jin-Sung Park

OP 166 | Clinical, Immunological and Metabolomic Risk Factors associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez

OP 167 | Inflammatory myopathy with severe cardiac involvement associated with anti-mitochondrial antibodies treated with rituximab and azathioprine: a case report
Silva Puksic

OP 187 | Anti-TIF1γ Antibody as an Early Screening Tool for Malignancy: A Case of Cancer-Associated Dermatomyositis Leading to Early Breast Cancer Diagnosis
Eiman Soliman

OP 196 | Efficacy and safety of up-front add-on IVIG in Juvenile Dermatomyositis: Single-center cohort study in 21 patients
Renske Kamperman

OP 202 | Elevated Serum CK Alone Is Insufficient As An Indicator Of AKI In Patients With Exertional Rhabdomyolysis
Amir Sabouri

OP 213 | Malignancy screening and prevalence in patients with idiopathic inflammatory myopathies
Ophir Vinik

OP 214 | MyoPreg: Registry for pregnancy outcomes in idiopathic inflammatory myopathies – a call for cooperation
Melinda Nagy-Vincze

OP 222 | Refractory anti-HMGCR-Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to JAK Inhibitor: A Case Report
Vladimir Liarski

OP 248 | Seasonal pattern of myositis relapse and tumor recurrence in cancer-associated dermatomyositis: a multicenter case series
Silvia Grazzini

OP 251 | INTERFERON SIGNALIZATION IN JUVENILE DERMATOMYOSITIS
Sara S. Kilic

OP 260 | ANCA-Associated Vasculitis Presenting with Isolated Myositis: A Diagnostic Challenge
Anita Cunha

OP 275 | Design and rationale for a randomized, double-blind, placebo-controlled phase 2/3 study of Descartes-08, mRNA CAR T-cell therapy, in adults with Dermatomyositis and Antisynthetase Syndrome
Tahseen Mozaffar

OP 279 | Evaluating Generative AI for Patient Self-Education in Rare Diseases: A Pilot Study in Myositis
Pritikanta Paul

OP 281 | Phase 1/2 dose-escalation basket study of Descartes-08, mRNA CAR T-cell therapy, in juvenile autoimmune diseases: design and rationale.
Anant Vatsayan

OP 288 | Intravenous Immunoglobulin as effective therapy for refractory cutaneous anti-TIF1-γ dermatomyositis
Jorge Lindo

OP 289 | Panniculitis in Anti-TIF1-γ Dermatomyositis
Jorge Lindo

OP 323 | Lung disease as the first glimpse of an inflammatory myopathy: a case series
Filipa Canhão André

OP 354 | Towards a nationwide myositis database – The Dutch Myositis Registry
Nienke Heida

OP 359 | Concomitant Intravenous Immunoglobulin and Anifrolumab in Lupus and Dermatomyositis Patients: Real-World Data From a Retrospective Cohort Study
Kathryn Rentfro